Skip to main content

Catalio Capital Management — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

132
Companies
$12.7B
Total invested
$93.1M
Avg. check
21
Industries
Biotechnology 19Health Care 16Medical 9Therapeutics 8Life Science 6Biopharma 5+15 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 4972 of 132
SetPoint Medical
August 2025

SetPoint Medical provides a device-based therapy for rheumatoid arthritis.

Biotechnology · Valencia$115.0M Series D
Avalyn Pharma
July 2025

Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.

Biopharma · Seattle$100.0M Series D
Syndeio Biosciences
May 2025

Syndeio Biosciences is a newly launched biotech company pioneering precision neurotherapeutics.

Biotechnology · Indianapolis$90.0M Venture - Series Unknown
GlycoEra
May 2025

GlycoEra is a biotechnology research company that produces extracellular protein degraders for the treatment of autoimmune diseases.

Biotechnology · Schlieren$130.0M Series B
Imbria Pharmaceuticals
April 2025

Imbria Pharmaceuticals is a clinical stage biotechnology company developing novel therapies for cardiometabolic diseases.

Biotechnology · Boston$59.2M Series B
Elektrofi
August 2024

Elektrofi is a preclinical-stage company dedicated to redefining the standard of drug delivery by transforming the patient experience.

Alternative Medicine · Boston$112.3M Series C
Roshal Imaging Services
February 2024

Roshal Imaging Services is a provider of on-site and portable diagnostic Vascular and General body (OB/Gyn) ultrasound services.

Health Care · Katy$10.0M Venture - Series Unknown
OnCusp Therapeutics
January 2024

OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments.

Biotechnology · New York$100.0M Series A
Lassen Therapeutics
December 2023

Lassen Therapeutics develops antibody biotherapeutics to help improve the lives of patients suffering from serious diseases.

Biotechnology · San Diego$85.0M Series B
Georgiamune
August 2023

Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.

Biotechnology · Gaithersburg$75.0M Series A
Aviceda Therapeutics
January 2025

Aviceda Therapeutics is a late-stage pre-clinical biotech company developing drugs for treating glyco-immune diseases.

Biotechnology · Cambridge$207.5M Series C
Metagenomi
January 2023

Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development.

Artificial Intelligence (AI) · Emeryville$100.0M Series B
Perceive Biotherapeutics
January 2023

Perceive Biotherapeutics is a biotechnology company pioneering novel technologies and therapeutics in ophthalmology.

Biopharma · South San Francisco$78.0M Series B
Medical Informatics
January 2025

Medical Informatics offers solutions that give care teams access to the data they need to take action for alarm management and safety.

Health Care · Houston$5.0M Debt Financing
Sidera Bio
December 2025

Sidera Bio harness human genetics, that helps in transformative medicines for patients.

Genetics · Copenhagen$109.0M Series A
Protara Therapeutics
December 2025

Protara Therapeutics develops transformative therapies for people with cancer and rare diseases with limited treatment options.

Biotechnology · New York$75.0M Post-IPO Equity
PinkDx
January 2025

PinkDx is a biotechnology company.

Biopharma · Indianapolis$5.0M Series A
Glympse Bio
December 2021

Glympse Bio is a biotechnology company that transforms disease detection and predict treatment response.

Biotechnology · Cambridge$18.0M Venture - Series Unknown
Medra AI
December 2025

Medra AI develops an autonomous scientific experimentation platform that combines robotics with artificial intelligence.

Artificial Intelligence (AI) · San Francisco$52.0M Series A
PrognomiQ
January 2026

PrognomiQ is a biotechnology firm that develops test products to detect early disease detection through the power of multi-omics data.

Biopharma · San Mateo$11.9M Venture - Series Unknown
Sherlock Biosciences
November 2022

Sherlock Biosciences is an engineering biology company offering unparalleled breadth and versatility for diagnostic solutions.

Biotechnology · CambridgeGrant
Sentonix
January 2025

Sentonix is a pharmaceutical company that offers immuno-therapy service for cancer treatment.

Biopharma · ArlingtonSeed
Thrive Earlier Detection
January 2023

Thrive Earlier Detection is a healthcare company that integrates earlier cancer detection into routine medical care.

Biotechnology · CambridgeVenture - Series Unknown
Volta Labs
January 2024

Volta Labs develops scalable automation for genetic engineering.

Biometrics · CambridgeVenture - Series Unknown

Where Catalio Capital Management invests

Biotechnology19
Health Care16
Medical9
Therapeutics8
Life Science6
Biopharma5

About Catalio Capital Management's portfolio

How many companies has Catalio Capital Management invested in?

Catalio Capital Management has invested in 132 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Catalio Capital Management invest in?

Catalio Capital Management's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Life Science. The firm invests across 21 different industry categories.

What is Catalio Capital Management's largest investment?

Among tracked funding rounds, Aviceda Therapeutics received $207.5M in a Series C round. Catalio Capital Management's total known invested capital is $12.7B.

What is the average investment size for Catalio Capital Management?

Catalio Capital Management's average investment size is $93.1M across its portfolio of 132 companies.

What are Catalio Capital Management's most recent investments?

Recent Catalio Capital Management portfolio additions include SetPoint Medical, Avalyn Pharma, Syndeio Biosciences, GlycoEra, Imbria Pharmaceuticals. These companies were founded in 2020 or later.

Reach the founders behind these 132 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →